DOID:1749

Name:	squamous cell carcinoma
Definition:	"A carcinoma that derives_from squamous epithelial cells." [url:http\://en.wikipedia.org/wiki/Squamous_cell_carcinoma, url:http\://www.medicinenet.com/skin_cancer/page2.htm]
Synonyms:	"epidermoid carcinoma" EXACT [CSP2005:2000-3145] "malignant squamous cell tumor" EXACT [NCI2004_11_17:C4971] "squamous carcinoma" EXACT [NCI2004_11_17:C2929] "squamous cell cancer" EXACT [] "squamous cell carcinoma (disorder)" EXACT [SNOMEDCT_2005_07_31:402815007] "squamous cell carcinoma (morphologic abnormality)" EXACT [SNOMEDCT_2005_07_31:28899001] "squamous cell carcinoma NOS (morphologic abnormality)" EXACT [SNOMEDCT_2005_07_31:189566008] "squamous cell Epithelioma" EXACT [NCI2004_11_17:C8999]
Alt_id:	DOID:5512

Ontology association<br>Each term has an is_a parent in the Disease Ontology, which has a linkage to an another entity and FANTOM5 samples.Libraries were grouped into mutually exclusive facets according to the FANTOM5 sample ontology mapping to DISEASE ontologies.<br><br>link to ontology dataset<br>data

---

Parents

is_a:	DOID:305(carcinoma)

Children

is a:	DOID:4830 (adenosquamous carcinoma)

Ontology Tree: Loaded from BioPortal

Ontorolgy tree(Small window open)

FF samples

Human (Homo sapiens)

• 10412-106B7 (malignant trichilemmal cyst cell line:DJM-1)
• 10426-106D3 (epidermoid carcinoma cell line:A431)
• 10431-106D8 (epidermoid carcinoma cell line:Ca Ski)
• 10434-106E2 (oral squamous cell carcinoma cell line:Ca9-22)
• 10457-106G7 (squamous cell lung carcinoma cell line:LC-1F)
• 10463-106H4 (squamous cell carcinoma cell line:EC-GI-10)
• 10486-107A9 (squamous cell lung carcinoma cell line:EBC-1)
• 10501-107C6 (squamous cell lung carcinoma cell line:RERF-LC-AI)
• 10512-107D8
• 10532-107G1

... further results Mouse (Mus musculus)

• 10412-106B7 (malignant trichilemmal cyst cell line:DJM-1)
• 10426-106D3 (epidermoid carcinoma cell line:A431)
• 10431-106D8 (epidermoid carcinoma cell line:Ca Ski)
• 10434-106E2 (oral squamous cell carcinoma cell line:Ca9-22)
• 10457-106G7 (squamous cell lung carcinoma cell line:LC-1F)
• 10463-106H4 (squamous cell carcinoma cell line:EC-GI-10)
• 10486-107A9 (squamous cell lung carcinoma cell line:EBC-1)
• 10501-107C6 (squamous cell lung carcinoma cell line:RERF-LC-AI)
• 10512-107D8
• 10532-107G1

... further results

Enrichment analysis: top 100 FFCP enriched with this ontology termTOP 100 FANTOM5 Cage Peaks enriched with DOID:1749 (squamous cell carcinoma), sorted by p-values <br>Analyst: Hideya Kawaji<br><br>link to source dataset <br>human : data <br>mouse : data

---

Copy Excel CSV PDF

Show 102550100 entries

Search:

P-value	FFCP	Short description

P-value	FFCP	Short description
1.52e-75	FFCP PHASE2:Hg19::chr1:209944599..209944616,-	p@chr1:209944599..209944616, -
1.52e-75	FFCP PHASE1:Hg19::chr1:209944599..209944616,-	p@chr1:209944599..209944616, -
2.65e-72	FFCP PHASE2:Hg19::chr11:70245655..70245668,-	p@chr11:70245655..70245668, -
2.65e-72	FFCP PHASE1:Hg19::chr11:70245655..70245668,-	p@chr11:70245655..70245668, -
2.04e-63	FFCP PHASE2:Hg19::chr1:55436540..55436544,-	p@chr1:55436540..55436544, -
2.04e-63	FFCP PHASE1:Hg19::chr1:55436540..55436544,-	p@chr1:55436540..55436544, -
3.14e-63	FFCP PHASE1:Hg19::chr7:55053327..55053342,+	p@chr7:55053327..55053342, +
3.14e-63	FFCP PHASE2:Hg19::chr7:55053327..55053342,+	p@chr7:55053327..55053342, +
8.34e-63	FFCP PHASE2:Hg19::chr3:151034414..151034434,-	p2@GPR87
8.34e-63	FFCP PHASE1:Hg19::chr3:151034414..151034434,-	p2@GPR87
1.33e-60	FFCP PHASE1:Hg19::chr6:19418214..19418218,-	p@chr6:19418214..19418218, -
1.33e-60	FFCP PHASE2:Hg19::chr6:19418214..19418218,-	p@chr6:19418214..19418218, -
4.0e-57	FFCP PHASE2:Hg19::chr1:209945462..209945477,-	p@chr1:209945462..209945477, -
4.0e-57	FFCP PHASE1:Hg19::chr1:209945462..209945477,-	p@chr1:209945462..209945477, -
4.38e-56	FFCP PHASE1:Hg19::chr7:55053266..55053282,+	p@chr7:55053266..55053282, +
4.38e-56	FFCP PHASE2:Hg19::chr7:55053266..55053282,+	p@chr7:55053266..55053282, +
4.21e-53	FFCP PHASE2:Hg19::chr1:153530641..153530645,-	p@chr1:153530641..153530645, -
4.21e-53	FFCP PHASE1:Hg19::chr1:153530641..153530645,-	p@chr1:153530641..153530645, -
5.73e-53	FFCP PHASE2:Hg19::chr21:38631055..38631068,-	p@chr21:38631055..38631068, -
5.73e-53	FFCP PHASE1:Hg19::chr21:38631055..38631068,-	p@chr21:38631055..38631068, -
1.69e-50	FFCP PHASE2:Hg19::chr8:126044339..126044344,-	p@chr8:126044339..126044344, -
1.69e-50	FFCP PHASE1:Hg19::chr8:126044339..126044344,-	p@chr8:126044339..126044344, -
2.43e-49	FFCP PHASE1:Hg19::chr17:39755734..39755747,-	p@chr17:39755734..39755747, -
2.43e-49	FFCP PHASE2:Hg19::chr17:39755734..39755747,-	p@chr17:39755734..39755747, -
2.53e-46	FFCP PHASE1:Hg19::chr10:54215029..54215039,-	p5@ENST00000435813, p5@uc001jjs.2
2.53e-46	FFCP PHASE2:Hg19::chr10:54215029..54215039,-	p5@ENST00000435813, p5@uc001jjs.2
1.76e-45	FFCP PHASE1:Hg19::chr18:61586483..61586487,+	p@chr18:61586483..61586487, +
1.76e-45	FFCP PHASE2:Hg19::chr17:39675950..39675974,-	p@chr17:39675950..39675974, -
1.76e-45	FFCP PHASE1:Hg19::chr17:39675950..39675974,-	p@chr17:39675950..39675974, -
1.76e-45	FFCP PHASE2:Hg19::chr18:61586483..61586487,+	p@chr18:61586483..61586487, +
4.38e-44	FFCP PHASE2:Hg19::chr3:153697368..153697372,+	p@chr3:153697368..153697372, +
4.38e-44	FFCP PHASE1:Hg19::chr3:153697368..153697372,+	p@chr3:153697368..153697372, +
1.27e-43	FFCP PHASE1:Hg19::chr19:51523412..51523427,-	p2@KLK10
1.27e-43	FFCP PHASE2:Hg19::chr19:51523412..51523427,-	p2@KLK10
4.85e-43	FFCP PHASE2:Hg19::chrX:15683147..15683159,-	p3@TMEM27
4.85e-43	FFCP PHASE2:Hg19::chr7:55053219..55053226,+	p@chr7:55053219..55053226, +
4.85e-43	FFCP PHASE1:Hg19::chr17:39675882..39675894,-	p@chr17:39675882..39675894, -
4.85e-43	FFCP PHASE1:Hg19::chrX:15683147..15683159,-	p3@TMEM27
4.85e-43	FFCP PHASE1:Hg19::chr7:55053219..55053226,+	p@chr7:55053219..55053226, +
4.85e-43	FFCP PHASE2:Hg19::chr17:39675882..39675894,-	p@chr17:39675882..39675894, -
1.42e-40	FFCP PHASE2:Hg19::chr13:74071880..74071894,+	p@chr13:74071880..74071894, +
1.42e-40	FFCP PHASE1:Hg19::chr13:74071880..74071894,+	p@chr13:74071880..74071894, +
1.5e-40	FFCP PHASE2:Hg19::chr5:150998590..150998611,-	p@chr5:150998590..150998611, -
1.5e-40	FFCP PHASE1:Hg19::chr5:150998590..150998611,-	p@chr5:150998590..150998611, -
2.02e-40	FFCP PHASE2:Hg19::chrX:41765898..41765915,-	p@chrX:41765898..41765915, -
2.02e-40	FFCP PHASE1:Hg19::chrX:41765898..41765915,-	p@chrX:41765898..41765915, -
6.43e-40	FFCP PHASE2:Hg19::chr20:30153874..30153891,+	p8@HM13
6.43e-40	FFCP PHASE1:Hg19::chr20:30153874..30153891,+	p8@HM13
2.28e-39	FFCP PHASE1:Hg19::chr17:72940334..72940358,+	p@chr17:72940334..72940358, +
2.28e-39	FFCP PHASE2:Hg19::chr17:72940334..72940358,+	p@chr17:72940334..72940358, +
2.41e-39	FFCP PHASE1:Hg19::chr10:54259403..54259416,+	p@chr10:54259403..54259416, +
2.41e-39	FFCP PHASE2:Hg19::chr10:54259403..54259416,+	p@chr10:54259403..54259416, +
4.5e-38	FFCP PHASE2:Hg19::chr7:55053540..55053550,+	p@chr7:55053540..55053550, +
4.5e-38	FFCP PHASE1:Hg19::chr7:55053540..55053550,+	p@chr7:55053540..55053550, +
2.13e-37	FFCP PHASE1:Hg19::chr11:57558934..57558956,+	p8@CTNND1
2.13e-37	FFCP PHASE2:Hg19::chr11:57558934..57558956,+	p8@CTNND1
1.18e-36	FFCP PHASE2:Hg19::chr12:20975224..20975226,-	p@chr12:20975224..20975226, -
1.18e-36	FFCP PHASE1:Hg19::chr12:20975224..20975226,-	p@chr12:20975224..20975226, -
2.27e-36	FFCP PHASE2:Hg19::chr20:52784969..52785020,+	p@chr20:52784969..52785020, +
2.27e-36	FFCP PHASE1:Hg19::chr20:52784969..52785020,+	p@chr20:52784969..52785020, +
2.56e-36	FFCP PHASE2:Hg19::chr17:39678090..39678101,-	p4@KRT15
2.56e-36	FFCP PHASE1:Hg19::chr5:39255776..39255791,+	p@chr5:39255776..39255791, +
2.56e-36	FFCP PHASE1:Hg19::chr17:39678090..39678101,-	p4@KRT15
2.56e-36	FFCP PHASE2:Hg19::chr5:39255776..39255791,+	p@chr5:39255776..39255791, +
3.32e-36	FFCP PHASE2:Hg19::chr2:31607762..31607771,-	p@chr2:31607762..31607771, -
3.32e-36	FFCP PHASE1:Hg19::chr2:31607762..31607771,-	p@chr2:31607762..31607771, -
1.21e-35	FFCP PHASE2:Hg19::chr9:114557207..114557230,-	p1@C9orf84
1.21e-35	FFCP PHASE1:Hg19::chr9:114557207..114557230,-	p1@C9orf84
1.94e-35	FFCP PHASE1:Hg19::chr9:114490545..114490560,-	p@chr9:114490545..114490560, -
1.94e-35	FFCP PHASE2:Hg19::chr9:114490545..114490560,-	p@chr9:114490545..114490560, -
7.61e-35	FFCP PHASE2:Hg19::chr7:20257377..20257401,+	p@chr7:20257377..20257401, +
7.61e-35	FFCP PHASE1:Hg19::chr7:20257377..20257401,+	p@chr7:20257377..20257401, +
8.78e-35	FFCP PHASE1:Hg19::chr8:128306991..128307011,-	p@chr8:128306991..128307011, -
8.78e-35	FFCP PHASE2:Hg19::chr8:128306991..128307011,-	p@chr8:128306991..128307011, -
1.37e-34	FFCP PHASE2:Hg19::chr20:10400400..10400411,-	p@chr20:10400400..10400411, -
1.37e-34	FFCP PHASE1:Hg19::chr20:10400400..10400411,-	p@chr20:10400400..10400411, -
2.01e-34	FFCP PHASE2:Hg19::chr14:51955719..51955733,+	p15@FRMD6
2.01e-34	FFCP PHASE1:Hg19::chr14:51955719..51955733,+	p15@FRMD6
2.93e-34	FFCP PHASE1:Hg19::chr11:393795..393799,-	p@chr11:393795..393799, -
2.93e-34	FFCP PHASE2:Hg19::chr11:393795..393799,-	p@chr11:393795..393799, -
5.36e-34	FFCP PHASE1:Hg19::chr6:10413321..10413336,+	p@chr6:10413321..10413336, +
5.36e-34	FFCP PHASE2:Hg19::chr6:10413321..10413336,+	p@chr6:10413321..10413336, +
5.82e-34	FFCP PHASE1:Hg19::chr1:115212619..115212636,-	p2@DENND2C
5.82e-34	FFCP PHASE2:Hg19::chr1:115212619..115212636,-	p2@DENND2C
6.3e-34	FFCP PHASE2:Hg19::chr10:105796014..105796053,-	p@chr10:105796014..105796053, -
6.3e-34	FFCP PHASE1:Hg19::chr10:105796014..105796053,-	p@chr10:105796014..105796053, -
8.11e-34	FFCP PHASE1:Hg19::chr11:57558973..57558988,+	p11@CTNND1
8.11e-34	FFCP PHASE2:Hg19::chr11:57558973..57558988,+	p11@CTNND1
1.5e-33	FFCP PHASE2:Hg19::chr6:43423785..43423800,-	p3@DLK2
1.5e-33	FFCP PHASE1:Hg19::chr6:43423785..43423800,-	p3@DLK2
7.55e-33	FFCP PHASE2:Hg19::chr15:79296820..79296829,-	p@chr15:79296820..79296829, -
7.55e-33	FFCP PHASE1:Hg19::chr15:79296820..79296829,-	p@chr15:79296820..79296829, -
1.14e-32	FFCP PHASE2:Hg19::chr12:47628434..47628438,+	p1@CU678929
1.14e-32	FFCP PHASE1:Hg19::chr12:47628434..47628438,+	p1@CU678929
1.46e-32	FFCP PHASE2:Hg19::chr12:52525577..52525579,-	p@chr12:52525577..52525579, -
1.46e-32	FFCP PHASE2:Hg19::chr17:76628163..76628174,-	p@chr17:76628163..76628174, -
1.46e-32	FFCP PHASE1:Hg19::chr12:52525577..52525579,-	p@chr12:52525577..52525579, -
1.46e-32	FFCP PHASE2:Hg19::chr20:10750941..10750951,+	p@chr20:10750941..10750951, +
1.46e-32	FFCP PHASE1:Hg19::chr20:10750941..10750951,+	p@chr20:10750941..10750951, +
1.46e-32	FFCP PHASE1:Hg19::chr17:76628163..76628174,-	p@chr17:76628163..76628174, -

Showing 1 to 100 of 100 entries